Toby M. Maher - Concepedia

Author

Toby M. Maher

Also Known As

Caroline Fromson, D Churchill, DA Schwartz, De Lauretis, Angelo, Elżbieta Radzikowska, Huzaifa I Adamali, JM Oldham, Justin M Oldham, Justin M. Oldham, Klaus-Uwe Kirchgaessler

988

Publications

33.4K

Citations

H-Index

128

Concepts

All Affiliations

Imperial College London Royal Brompton Hospital University of Southern California University College London Lung Institute

About

Toby M. Maher is an author at Imperial College London specializing in medicine, pulmonary fibrosis, and pulmonary disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	46	5.7K
2	Public Health	5	5	452
3	Engineering	3	3	90
4	Health Sciences	3	3	447
5	Business	1	1	54

Toby M. Maher

223

Publications

23.2K

Citations

H-Index

Page 1

	Year	Citations
Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease Oliver Distler, Kristin B. Highland, Martina Gahlemann, New England Journal of Medicine	2019	1.5K
Interstitial Lung Disease in Systemic Sclerosis Nicole Goh, Sujal R. Desai, Srihari Veeraraghavan, American Journal of Respiratory and Critical Care Medicine	2008	1.2K
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial Toby M. Maher, Tamera J. Corte, Aryeh Fischer, The Lancet Respiratory Medicine Antifibrotic TherapyAdvanced Lung DiseasePulmonary FibrosisPulmonary MedicineMedicine	2019	606
The Role of Bacteria in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis Philip L. Molyneaux, Michael J. Cox, Saffron A.G. Willis‐Owen, American Journal of Respiratory and Critical Care Medicine	2014	540
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown, The Lancet Respiratory Medicine Inbuild TrialParallel-group TrialAdvanced Lung DiseasePulmonary FibrosisPulmonary Medicine	2020	522
Pulmonary fibrosis secondary to COVID-19: a call to arms? Paolo Spagnolo, Elisabetta Balestro, Stefano Aliberti, The Lancet Respiratory Medicine	2020	490
Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes Taryn Reddy, Masaki Tominaga, David M. Hansell, European Respiratory Journal Recurrent InfectionsFibrosisUpper LobeMedical ImagingPleuroparenchymal Fibroelastosis	2012	377
PD-1 up-regulation on CD4 <sup>+</sup> T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production Lindsay J. Celada, Jonathan A. Kropski, Jose D. Herazo‐Maya, Science Translational Medicine	2018	354
Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis Nicole Goh, Rachel K. Hoyles, Christopher P. Denton, Arthritis & Rheumatology	2017	342
Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis Richard J. Allen, Beatriz Guillén‐Guío, Justin M. Oldham, American Journal of Respiratory and Critical Care Medicine	2019	323

Page 1